Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients.

These pivotal trials follow on the BELMONT study announced last year that showed RT002 delivered 6-month duration of effect, with no ptosis at the 40-unit level, in treating frown lines.

RT002 is Revance’s proprietary, investigational injectable botulinum toxin. It is a pure, 150kD botulinum toxin, type A molecule without any accessory proteins or animal-derived components.  RT002 incorporates the patented TransMTS^® peptide technology and is designed to provide a longer duration of effect.